4,5-diallylbenzene-1,2-diol | 13620-83-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 4,5-diallylbenzene-1,2-diol
• 英文别名: 4,5-Diallyl-brenzkatechin；4,5-Bis(prop-2-enyl)benzene-1,2-diol
• CAS: 13620-83-2
• 化学式: C₁₂H₁₄O₂
• 分子量: 190.242
• InChiKey: HUPKYJVMFZEFOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  邻苯二酚 、 3-溴丙烯 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 1.5h， 以8.18%的产率得到4,5-diallylbenzene-1,2-diol
  参考文献：
  名称：

  SUBSTITUTED CATHECHOLS AS INHIBITORS OF IL-4 AND IL-5 FOR THE TREATMENT BRONCHIAL ASTHMA

  摘要：

  本发明涉及通式1的化合物，用于通过抑制IL-4或IL-5途径的抑制治疗支气管哮喘。本发明还涉及使用通式1的化合物通过抑制IL-4或IL-5途径的抑制治疗支气管哮喘。本发明还涉及通过口服、鼻内、或吸入途径向需要治疗的哺乳动物给予化合物或所述组合物来抑制IL-4或IL-5途径以治疗哮喘的方法。通式1的化合物可用于减少周围血管和支气管炎症。

  公开号：

  US20140135393A1

文献信息

• [EN] INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE (PI3) AND INDUCERS OF NITRIC OXIDE (NO)<br/>[FR] INHIBITEURS DE LA PHOSPHATIDYLINOSITOL-3-KINASE (PI3) ET INDUCTEURS D'OXYDE NITRIQUE (NO)
  申请人：COUNCIL SCIENT IND RES

  公开号：WO2010079423A1

  公开（公告）日：2010-07-15

  The present invention relates to compounds of general formula 1 for the treatment of malignancy by inhibition of PI3-Akt pathway and or induction of NO. The present invention also relates to the use of compound of general formula 1 for the treatment of malignancy by inhibition of PI3-Akt pathway and or induction of NO. The present invention further relates to a method of treating malignancy by inhibition of PI3-Akt pathway and or induction of NO by administration of compound or said composition to a mammal in need thereof.

  本发明涉及通式1的化合物，通过抑制PI3-Akt通路和/或诱导NO来治疗恶性肿瘤。本发明还涉及使用通式1的化合物通过抑制PI3-Akt通路和/或诱导NO来治疗恶性肿瘤。本发明还涉及通过向需要该治疗的哺乳动物给予该化合物或该组合物来抑制PI3-Akt通路和/或诱导NO治疗恶性肿瘤的方法。
• INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE (PI3) AND INDUCERS OF NITRIC OXIDE (NO)
  申请人：Bandyopadhyay Santu

  公开号：US20120190738A1

  公开（公告）日：2012-07-26

  The present invention relates to compounds of general formula I for the treatment of malignancy by inhibition of PI3-Akt pathway and or induction of NO. The present invention also relates to the use of compound of general formula I for the treatment of malignancy by inhibition of PI3-Akt pathway and or induction of NO. The present invention further relates to a method of treating malignancy by inhibition of PI3-Akt pathway and or induction of NO by administration of compound or said composition to a mammal in need thereof.

  本发明涉及一般式I的化合物，通过抑制PI3-Akt途径和/或诱导NO治疗恶性肿瘤。本发明还涉及使用一般式I的化合物通过抑制PI3-Akt途径和/或诱导NO治疗恶性肿瘤。本发明还涉及一种通过向需要该治疗的哺乳动物给予化合物或所述组合物来抑制PI3-Akt途径和/或诱导NO治疗恶性肿瘤的方法。
• Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
  申请人：Race Oncology Ltd.

  公开号：US10548876B2

  公开（公告）日：2020-02-04

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.

  本发明描述了通过提高单一疗法的疗效或减少副作用来改善以前因治疗效果不理想而受到限制的治疗剂的疗效的方法和组合物。这些方法和组合物尤其适用于双蒽或其衍生物、类似物或原药。
• Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
  申请人：Race Oncology Ltd.

  公开号：US11147800B2

  公开（公告）日：2021-10-19

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.

  本发明描述了通过提高单一疗法的疗效或减少副作用来改善以前因治疗效果不理想而受到限制的治疗剂的疗效的方法和组合物。这些方法和组合物尤其适用于双蒽或其衍生物、类似物或原药。
• COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE
  申请人：Update Pharma Inc.

  公开号：EP3024457A1

  公开（公告）日：2016-06-01